[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626796":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":31,"centralContacts":36,"locations":43,"responsibleParty":385,"collaborators":387,"id":397,"slug":398,"hasResults":399,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":399,"sex":405,"minAge":406,"maxAge":41,"enrollmentInfo":407,"targetDuration":41,"studyType":410,"phases":411,"briefSummary":414,"conditions":415,"keywords":435,"overallStatus":451,"whyStopped":41,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":461},{"fullName":5,"class":6},"Cancer Research UK","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm 07: Dabrafenib and Trametinib","EXPERIMENTAL","This dabrafenib and trametinib treatment arm is for adult, paediatric and TYA patients with cancers harbouring BRAF V600 mutations.",[13,14],"Drug: Dabrafenib","Drug: Trametinib",[16,24],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Dabrafenib","Adult patients (≥18 years) will receive dabrafenib at a dose of 150 mg (two 75 mg tablets) twice daily (total daily dose 300 mg) throughout each 28-day cycle.\n\nPaediatric patients (1 to \\\u003C12 years) will receive dabrafenib dose adjusted by body weight as 10 mg dispersible tablets orally twice daily throughout each 28-day cycle.\n\nPaediatric patients (12-15 years) and TYA patients (16 to \\\u003C18 years) will have the option to receive adult or paediatric dosing.\n\nPatients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[9],[22,23],"Tafinlar","Finlee",{"type":17,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Trametinib","Adult patients (≥18 years) will receive trametinib at a daily dose of 2 mg (one 2 mg tablet) orally once daily (total daily dose 2 mg) throughout the 28-day cycle.\n\nPaediatric patients (1 to \\\u003C12 years) receive trametinib at a dose adjusted by body weight as 0.05 mg\u002Fm\\^2 powder for oral solution once daily throughout each 28-day cycle.\n\nPaediatric patients (12-15 years) and TYA patients (16 to \\\u003C18 years) will have the option to receive adult or paediatric dosing.\n\nPatients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.",[9],[29,30],"Mekinist","Spexotras",[32],{"name":33,"affiliation":34,"role":35},"Matthew Krebs","The Christie Hospital","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Aida Sarmiento Castro","CONTACT","+44 207 242 0200",null,"determine@cancer.org.uk",[44,60,74,85,99,107,121,136,147,161,175,186,200,214,228,239,250,264,274,288,302,311,325,333,347,358,371],{"facility":45,"status":41,"city":46,"state":41,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Belfast City Hospital","Belfast","BT9 7AB","United Kingdom","UK",{"type":51,"coordinates":52},"Point",[53,54],-5.92541,54.59682,{"lat":54,"lon":53},[57],{"name":58,"role":39,"phone":41,"phoneExt":41,"email":59},"Vicky Coyle, Prof","V.Coyle@qub.ac.uk",{"facility":61,"status":41,"city":62,"state":41,"zip":63,"country":48,"countryCode":49,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"University Hospital Birmingham","Birmingham","B15 2TT",{"type":51,"coordinates":65},[66,67],-1.89983,52.48142,{"lat":67,"lon":66},[70],{"name":71,"role":39,"phone":72,"phoneExt":41,"email":73},"Gary Middleton, Prof","+44 (0)121 371 3573","G.Middleton@bham.ac.uk",{"facility":75,"status":41,"city":62,"state":41,"zip":76,"country":48,"countryCode":49,"cosmosGeoPoint":77,"geoPoint":79,"contacts":80},"Birmingham Children's Hospital","B4 6NH",{"type":51,"coordinates":78},[66,67],{"lat":67,"lon":66},[81],{"name":82,"role":39,"phone":83,"phoneExt":41,"email":84},"Gerard Millen, Dr","+44 (0)7921843607","G.Millen@nhs.net",{"facility":86,"status":41,"city":87,"state":41,"zip":88,"country":48,"countryCode":49,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Bristol Royal Hospital for Children","Bristol","BS2 8BJ",{"type":51,"coordinates":90},[91,92],-2.59665,51.45523,{"lat":92,"lon":91},[95],{"name":96,"role":39,"phone":97,"phoneExt":41,"email":98},"Antony Ng, Dr","+44 (0)117 342 8044","Antony.Ng@uhbw.nhs.uk",{"facility":100,"status":41,"city":87,"state":41,"zip":101,"country":48,"countryCode":49,"cosmosGeoPoint":102,"geoPoint":104,"contacts":105},"Bristol Haematology and Oncology Centre","BS2 8ED",{"type":51,"coordinates":103},[91,92],{"lat":92,"lon":91},[106],{"name":96,"role":39,"phone":97,"phoneExt":41,"email":98},{"facility":108,"status":41,"city":109,"state":41,"zip":110,"country":48,"countryCode":49,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Addenbrooke's Hospital","Cambridge","CB2 OQQ",{"type":51,"coordinates":112},[113,114],0.11667,52.2,{"lat":114,"lon":113},[117],{"name":118,"role":39,"phone":119,"phoneExt":41,"email":120},"Bristi Basu, Dr","+44 (0)1223 596105","Bristi.Basu@nhs.net",{"facility":122,"status":41,"city":123,"state":41,"zip":124,"country":48,"countryCode":49,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Velindre Cancer Centre","Cardiff","CF14 2TL",{"type":51,"coordinates":126},[127,128],-3.18,51.48,{"lat":128,"lon":127},[131],{"name":132,"role":39,"phone":133,"phoneExt":134,"email":135},"Robert Jones, Dr","+44 (0)2920 615888","6327","Robert.Hugh.Jones@wales.nhs.uk",{"facility":137,"status":41,"city":123,"state":41,"zip":138,"country":48,"countryCode":49,"cosmosGeoPoint":139,"geoPoint":141,"contacts":142},"Cardiff Children's Hospital","CF14 4XW",{"type":51,"coordinates":140},[127,128],{"lat":128,"lon":127},[143],{"name":144,"role":39,"phone":145,"phoneExt":41,"email":146},"Madeline Adams, Dr","+44 (0)292 184 2285","Madeline.Adams@wales.nhs.uk",{"facility":148,"status":41,"city":149,"state":41,"zip":150,"country":48,"countryCode":49,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Western General Hospital","Edinburgh","EH4 2XU",{"type":51,"coordinates":152},[153,154],-3.19648,55.95206,{"lat":154,"lon":153},[157],{"name":158,"role":39,"phone":159,"phoneExt":41,"email":160},"Stefan Symeonides, Dr","+44 (0)131 651 8500","Stefan.Symeonides@ed.ac.uk",{"facility":162,"status":41,"city":163,"state":41,"zip":164,"country":48,"countryCode":49,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"The Beatson Hospital","Glasgow","G12 OYN",{"type":51,"coordinates":166},[167,168],-4.25763,55.86515,{"lat":168,"lon":167},[171],{"name":172,"role":39,"phone":173,"phoneExt":41,"email":174},"Patricia Roxburgh, Dr","+44 (0)141 301 7118","Patricia.Roxburgh@glasgow.ac.uk",{"facility":176,"status":41,"city":163,"state":41,"zip":177,"country":48,"countryCode":49,"cosmosGeoPoint":178,"geoPoint":180,"contacts":181},"Royal Hospital for Children Glasgow","G51 4TF",{"type":51,"coordinates":179},[167,168],{"lat":168,"lon":167},[182],{"name":183,"role":39,"phone":184,"phoneExt":41,"email":185},"Milind Ronghe, Dr","+44 (0)141 452 6692","Milind.Ronghe@ggc.scot.nhs.uk",{"facility":187,"status":41,"city":188,"state":41,"zip":189,"country":48,"countryCode":49,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Leicester Royal Infirmary","Leicester","LE1 5WW",{"type":51,"coordinates":191},[192,193],-1.13169,52.6386,{"lat":193,"lon":192},[196],{"name":197,"role":39,"phone":198,"phoneExt":41,"email":199},"Harriet Walker, Dr","+44 (0)116 258 7602","Harriet.Walter1@nhs.net",{"facility":201,"status":41,"city":202,"state":41,"zip":203,"country":48,"countryCode":49,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Alder Hey Hospital","Liverpool","L14 5AB",{"type":51,"coordinates":205},[206,207],-2.97794,53.41058,{"lat":207,"lon":206},[210],{"name":211,"role":39,"phone":212,"phoneExt":41,"email":213},"Lisa Howell, Dr","+44 (0)151 293 3679","Lisa.Howell@alderhey.nhs.uk",{"facility":215,"status":41,"city":216,"state":41,"zip":217,"country":48,"countryCode":49,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"University College London Hospital","London","NW1 2BU",{"type":51,"coordinates":219},[220,221],-0.12574,51.50853,{"lat":221,"lon":220},[224],{"name":225,"role":39,"phone":226,"phoneExt":41,"email":227},"Martin Foster, Prof","+44 (0)20 3447 5085","M.Forster@ucl.ac.uk",{"facility":229,"status":41,"city":216,"state":41,"zip":230,"country":48,"countryCode":49,"cosmosGeoPoint":231,"geoPoint":233,"contacts":234},"Guy's Hopsital","SE1 9RT",{"type":51,"coordinates":232},[220,221],{"lat":221,"lon":220},[235],{"name":236,"role":39,"phone":237,"phoneExt":41,"email":238},"James Spicer, Dr","+44 (0)20 7188 4260","James.Spicer@kcl.ac.uk",{"facility":240,"status":41,"city":216,"state":41,"zip":241,"country":48,"countryCode":49,"cosmosGeoPoint":242,"geoPoint":244,"contacts":245},"Great Ormond Street Hospital","WC1N 3JH",{"type":51,"coordinates":243},[220,221],{"lat":221,"lon":220},[246],{"name":247,"role":39,"phone":248,"phoneExt":41,"email":249},"Darren Hargrave, Dr","+44 (0)207 813 8525","Darren.Hargrave@gosh.nhs.uk",{"facility":251,"status":41,"city":252,"state":41,"zip":253,"country":48,"countryCode":49,"cosmosGeoPoint":254,"geoPoint":258,"contacts":259},"Royal Manchester Children's Hospital","Manchester","M13 9WL",{"type":51,"coordinates":255},[256,257],-2.23743,53.48095,{"lat":257,"lon":256},[260],{"name":261,"role":39,"phone":262,"phoneExt":41,"email":263},"Guy Makin, Dr","+44 0161 701 8419","Guy.Makin@mft.nhs.uk",{"facility":34,"status":41,"city":252,"state":41,"zip":265,"country":48,"countryCode":49,"cosmosGeoPoint":266,"geoPoint":268,"contacts":269},"M20 4BX",{"type":51,"coordinates":267},[256,257],{"lat":257,"lon":256},[270],{"name":271,"role":39,"phone":272,"phoneExt":41,"email":273},"Matthew Krebs, Prof","+44 (0)161 918 7672","Matthew.Krebs@nhs.net",{"facility":275,"status":41,"city":276,"state":41,"zip":277,"country":48,"countryCode":49,"cosmosGeoPoint":278,"geoPoint":282,"contacts":283},"Clatterbridge Cancer Centre","Metropolitan Borough of Wirral","CH63 4JY",{"type":51,"coordinates":279},[280,281],-3.10501,53.37616,{"lat":281,"lon":280},[284],{"name":285,"role":39,"phone":286,"phoneExt":41,"email":287},"Dan Palmer, Dr","+44 151 706 4172\u002F 151 706 4177","Daniel.Palmer@liverpool.ac.uk",{"facility":289,"status":41,"city":290,"state":41,"zip":291,"country":48,"countryCode":49,"cosmosGeoPoint":292,"geoPoint":296,"contacts":297},"Great North Children's Hospital","Newcastle","NE1 4LP",{"type":51,"coordinates":293},[294,295],-5.88979,54.21804,{"lat":295,"lon":294},[298],{"name":299,"role":39,"phone":300,"phoneExt":41,"email":301},"Alastair Greystoke, Dr","+44 (0)191 2138476","Alastair.Greystoke@newcastle.ac.uk",{"facility":303,"status":41,"city":290,"state":41,"zip":304,"country":48,"countryCode":49,"cosmosGeoPoint":305,"geoPoint":307,"contacts":308},"Freeman Hospital","NE7 7DN",{"type":51,"coordinates":306},[294,295],{"lat":295,"lon":294},[309],{"name":299,"role":39,"phone":300,"phoneExt":41,"email":310},"Greystoke@newcastle.ac.uk",{"facility":312,"status":41,"city":313,"state":41,"zip":314,"country":48,"countryCode":49,"cosmosGeoPoint":315,"geoPoint":319,"contacts":320},"Churchill Hospital","Oxford","OX3 7LE",{"type":51,"coordinates":316},[317,318],-1.25596,51.75222,{"lat":318,"lon":317},[321],{"name":322,"role":39,"phone":323,"phoneExt":41,"email":324},"Sarah Pratap, Dr","+44 (0)1865 235273","Sarah.Pratap@ouh.nhs.uk",{"facility":326,"status":41,"city":313,"state":41,"zip":327,"country":48,"countryCode":49,"cosmosGeoPoint":328,"geoPoint":330,"contacts":331},"John Radcliffe Hospital","OX3 9DU",{"type":51,"coordinates":329},[317,318],{"lat":318,"lon":317},[332],{"name":322,"role":39,"phone":323,"phoneExt":41,"email":324},{"facility":334,"status":41,"city":335,"state":41,"zip":336,"country":48,"countryCode":49,"cosmosGeoPoint":337,"geoPoint":341,"contacts":342},"Weston Park Hospital","Sheffield","S10 2SJ",{"type":51,"coordinates":338},[339,340],-1.4659,53.38297,{"lat":340,"lon":339},[343],{"name":344,"role":39,"phone":345,"phoneExt":41,"email":346},"Sarah Danson, Dr","+44 (0)114 226 5068","S.Danson@sheffield.ac.uk",{"facility":348,"status":41,"city":335,"state":41,"zip":349,"country":48,"countryCode":49,"cosmosGeoPoint":350,"geoPoint":352,"contacts":353},"Sheffield's Children's Hospital","S10 2TH",{"type":51,"coordinates":351},[339,340],{"lat":340,"lon":339},[354],{"name":355,"role":39,"phone":356,"phoneExt":41,"email":357},"Daniel Yeomanson, Dr","+44 (0)114 271 7366","danyeomanson@nhs.net",{"facility":359,"status":41,"city":360,"state":41,"zip":41,"country":48,"countryCode":49,"cosmosGeoPoint":361,"geoPoint":365,"contacts":366},"Southampton General Hospital","Southampton",{"type":51,"coordinates":362},[363,364],-1.40428,50.90395,{"lat":364,"lon":363},[367],{"name":368,"role":39,"phone":369,"phoneExt":41,"email":370},"Juliet Gray, Prof","+44 (0)238 120 6639","Juliet.Gray@uhs.nhs.uk",{"facility":372,"status":41,"city":373,"state":41,"zip":374,"country":48,"countryCode":49,"cosmosGeoPoint":375,"geoPoint":379,"contacts":380},"The Royal Marsden Hospital","Sutton","SM2 5PT",{"type":51,"coordinates":376},[377,378],-0.2,51.35,{"lat":378,"lon":377},[381],{"name":382,"role":39,"phone":383,"phoneExt":41,"email":384},"Lynley Marshall, Dr","+44 (0)208 661 3678","LynleyVanessa.Marshall@icr.ac.uk",{"type":386,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR",[388,390,392,395],{"name":389,"class":6},"University of Manchester",{"name":391,"class":6},"University of Birmingham",{"name":393,"class":394},"Novartis Pharmaceuticals UK Limited","UNKNOWN",{"name":396,"class":394},"Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research","100626796","phase-2-determine-trial-treatment-arm-07-dabrafenib-in-combination-with-trametinib-in-adult-paediatric-and-teenageyoung-adult-patients-with-braf-v600-mutation-positive-cancers-100626796",false,"NCT07440290","DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With BRAF V600 Mutation-Positive Cancers.","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and TYA Patients With BRAF V600 Mutation-Positive Cancers.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 07 (DABRAFENIB AND TRAMETINIB) OUTLINED BELOW\\* \\*When dabrafenib- and trametinib-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the dabrafenib- and trametinib-specific criteria will take precedence.\n\nInclusion criteria:\n\nA. Confirmed diagnosis of a malignancy harbouring an oncogenic alteration in BRAF V600, including Langerhans cell histiocytosis, using an analytically validated next-generation sequencing method.\n\nB. Patients ≥1 year old and ≥8 kg in body weight.\n\nC. Women of childbearing potential are eligible provided that they meet the following criteria:\n\n• Have a negative serum or urine pregnancy test before enrolment and;\n\n• Agree to use one form of a non-hormonal highly effective contraception method (a method that can achieve a failure rate of \\\u003C1% when used consistently and correctly; the requirement for non-hormonal method is because dabrafenib may decrease the efficacy of oral or any systemic hormonal contraceptives), such as: i. intrauterine device (IUD), ii. bilateral tubal occlusion, bilateral tubal ligation (at least six weeks before taking trial treatment), iii. vasectomised partner, iv. total sexual abstinence. Effective from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later).\n\nPatients who are breastfeeding must be willing to discontinue breastfeeding from the start of treatment, throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later).\n\nD. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks after the last administration of dabrafenib and 16 weeks after the last administration of trametinib (whichever is later):\n\n* Agree to take measures not to father children by using a barrier method of contraception (male condom plus spermicide) or to sexual abstinence.\n* Non-vasectomised male partners with partners who are women of childbearing potential should also be advised of the benefit for their partner of using a highly effective method of contraception, such as:\n\n  i. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal or transdermal\\]), ii. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), iii. IUD, iv. intrauterine hormone-releasing system (IUS), v. bilateral tubal occlusion, vi. total sexual abstinence.\n* Male patients with pregnant or breastfeeding partners must be advised to use barrier method contraception (male condom) to prevent drug exposure of the foetus or neonate, even if vasectomised.\n* Male patients must refrain from donating sperm for the same period.\n\nE. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nF. Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility\n\nExclusion criteria:\n\nA. Diagnosis of one of the following BRAF V600E mutation-positive cancers:\n\n* Colorectal cancer in adult (≥18 years) patients;\n* Unresectable or metastatic melanoma in adult (≥18 years) patients;\n* Advanced non-small cell lung cancer in adult (≥18 years) patients;\n* Gliomas harbouring a BRAF V600E mutation in paediatric (1 to \\\u003C16 years) or TYA (16 to \\\u003C18 years) patients.\n\nB. Previous treatment with dabrafenib and trametinib in combination (or other BRAF and MEK inhibitors in combination) for the current indication.\n\nC. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or for two weeks following their last dose of dabrafenib or 16 weeks following their last dose of trametinib, whichever is later.\n\nD. Known hypersensitivity to dabrafenib or trametinib or any of the excipients. See the current relevant SmPCs (UK) for the full lists.\n\nE. Patients with a history of retinal vein occlusion.\n\nF. Any impairment of gastrointestinal (GI) function of uncontrolled GI disease that may significantly alter the administration or absorption of dabrafenib and\u002For trametinib (e.g. history of diverticulitis, metastases to the GI tract, uncontrolled Crohn's disease, uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome or short gut syndrome).\n\nG. Clinically significant cardiac or cerebrovascular disease as defined by:\n\n* Unstable angina within three months prior to screening;\n* Myocardial infarction within three months prior to screening;\n* History of documented congestive heart failure (New York Heart Association functional classification III\u002FIV) etc.\n\nPatients with a cerebrovascular event (including stroke or transient ischaemic attack \\[TIA\\]) within three months prior to screening.\n\n• Patients with primary central nervous system (CNS) tumours may be considered unless intratumoural bleeding has occurred within two weeks prior to the first dose of dabrafenib and trametinib, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nH. Patients who were administered a live, attenuated vaccine within 28 days prior to initiation of treatment, or anticipation of need for such a vaccine during investigational medicinal product (IMP) treatment or within six months after the final dose of dabrafenib and trametinib.\n\nI. Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of dabrafenib and trametinib including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided that each of the following conditions are met:\n\n* CD4 count ≥350\u002FµL;\n* Undetectable viral load;\n* Receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* No HIV\u002Facquired immune deficiency syndrome associated opportunistic infection in the last 12 months.\n\nJ. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial (including absorption of oral medications) that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.","ALL","1 Year",{"count":408,"type":409},30,"ESTIMATED","INTERVENTIONAL",[412,413],"PHASE2","PHASE3","This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Dabrafenib and trametinib work in patients with a particular mutation in their cancer known as BRAF V600.\n\nInvestigators now wish to find out if they will be useful in treating patients with other cancer types which have the same mutation. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434],"Haematological Malignancy","Malignant Neoplasm","Lymphoproliferative Disorders","Neoplasms by Histologic Type","Neoplasms by Site","Gastrointestinal Cancer","Non-Melanoma Skin Cancer (NMSC)","Langerhans Cell Histiocytosis (LCH)","Cancer","Erdheim-Chester Disease","Thyroid Carcinoma, Papillary","Ovarian Neoplasms","Colorectal Neoplasms","Laryngeal Neoplasms","Carcinoma, Non-Small Cell-Lung","Glioma","Multiple Myeloma","Thyroid Carcinoma, Anaplastic","Solid Tumour",[436,437,424,438,18,439,440,441,442,443,420,444,445,446,447,448,25,449,450],"Adult","Antineoplastic Agents","Child","Malignancy","Malignant Neoplasms","Molecular Targeted Therapy","Mutation","Neoplasms by Histologic Site","Paediatric","Precision Medicine","Proto-Oncogene Proteins B-raf","Protein Kinase Inhibitors","Rare","Tumour-Agnostic","Young adult","NOT_YET_RECRUITING","2026-02-23",{"date":454,"type":455},"2026-02-27","ACTUAL",{"date":457,"type":409},"2026-02",{"date":459,"type":409},"2029-10",{"name":5,"class":6},27]